As Trump 2.0 speeds forward, the economy and the capital markets remain fixated on how policy changes will impact investor sentiment. With the biotech market trying to emerge from one of the worst downturns in history, strong headwinds remain, and generalists remain on the sidelines for high-beta sectors like biotech.

What are the key drivers that investors are watching that could help biotechs rise above the noise?

Join BioCentury’s Stephen Hansen and Oppenheimer’s Michael Margolis for an in-depth discussion with leading investors from the U.S. and Europe about where the biotech market is headed.